- Home
- HCI vs ORKA Comparison
HCI vs ORKA Comparison
Compare HCI & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCI
- ORKA
- Stock Information
- Founded
- HCI 2006
- ORKA 2004
- Country
- HCI United States
- ORKA United States
- Employees
- HCI N/A
- ORKA N/A
- Industry
- HCI Property-Casualty Insurers
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- HCI Finance
- ORKA Health Care
- Exchange
- HCI Nasdaq
- ORKA Nasdaq
- Market Cap
- HCI 1.7B
- ORKA 354.2M
- IPO Year
- HCI N/A
- ORKA N/A
- Fundamental
- Price
- HCI $139.35
- ORKA $14.21
- Analyst Decision
- HCI Strong Buy
- ORKA Strong Buy
- Analyst Count
- HCI 4
- ORKA 8
- Target Price
- HCI $181.25
- ORKA $39.71
- AVG Volume (30 Days)
- HCI 165.9K
- ORKA 360.1K
- Earning Date
- HCI 08-07-2025
- ORKA 08-15-2025
- Dividend Yield
- HCI 1.15%
- ORKA N/A
- EPS Growth
- HCI 4.05
- ORKA N/A
- EPS
- HCI 10.46
- ORKA N/A
- Revenue
- HCI $759,870,000.00
- ORKA N/A
- Revenue This Year
- HCI $19.25
- ORKA N/A
- Revenue Next Year
- HCI $4.08
- ORKA N/A
- P/E Ratio
- HCI $13.30
- ORKA N/A
- Revenue Growth
- HCI 20.95
- ORKA N/A
- 52 Week Low
- HCI $85.85
- ORKA $5.49
- 52 Week High
- HCI $176.40
- ORKA $52.32
- Technical
- Relative Strength Index (RSI)
- HCI 30.31
- ORKA N/A
- Support Level
- HCI $136.75
- ORKA N/A
- Resistance Level
- HCI $147.68
- ORKA N/A
- Average True Range (ATR)
- HCI 4.38
- ORKA 0.00
- MACD
- HCI -0.95
- ORKA 0.00
- Stochastic Oscillator
- HCI 15.20
- ORKA 0.00
About HCI HCI Group Inc.
HCI Group Inc is engaged in the property and casualty insurance business through two Florida domiciled insurance companies, Homeowners Choice Property & Casualty Insurance Company (HCPCI) and TypTap Insurance Company (TypTap). Both HCPCI and TypTap are authorized to underwrite various homeowners' property and casualty insurance products and allied lines business in the state of Florida and other states. The operating segments of the group are insurance operations, TypTap Group, reciprocal exchange operations, real estate operations, and corporate and other. It derives key revenue from the HCPCI Insurance operation segment.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.